The invention relates to HCMV ribonucleic acid (RNA) vaccines encoding i) HCMV antigenic polypeptides gH, gL, UL128, UL130, and/or UL131A, ii) HCMV antigenic polypeptide gB, iii) HCMV antigenic polypeptide pp65, and iv) a pharmaceutically acceptable carrier or excipient. Also HCMV polypeptide vaccines comprising (i)-(iv), HCMV mRNA vaccines comprising HCMV antigens, as well as methods of using the vaccines and compositions thereof.